{"id":"ly4065967","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The drug targets fibroblast growth factor receptors, which are frequently dysregulated in various cancers through mutations, amplifications, or translocations. By inhibiting FGFR kinase activity, LY4065967 suppresses downstream signaling pathways that drive cell proliferation and survival in FGFR-dependent tumors. This mechanism is particularly relevant in cancers with FGFR alterations, including certain lung, gastric, and other solid tumors.","oneSentence":"LY4065967 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:58:55.064Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-altered solid tumors (Phase 2 development)"}]},"trialDetails":[{"nctId":"NCT07285018","phase":"PHASE2","title":"A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-16","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":150},{"nctId":"NCT07039045","phase":"PHASE1","title":"A Study of [14C]-LY4065967 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2025-06-23","conditions":"Healthy","enrollment":16},{"nctId":"NCT06594159","phase":"PHASE1","title":"A Study of LY4065967 in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-10-22","conditions":"Healthy","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"LY4065967","genericName":"LY4065967","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY4065967 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation. Used for FGFR-altered solid tumors (Phase 2 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}